Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

1 Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy 2 Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy Dupilumab is a monoclonal antibody targeting ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

However, biologics like Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) Dupixent (dupilumab) have paved the way for a new treatment paradigm, targeting specific inflammatory pathways to reduce ...

Objective: This study analyzes the occurrence and characteristics of adverse drug reactions (ADRs) of dupilumab in children in a real-world setting. It aims to enhance clinical practice and minimize ...